Objectif Many common diseases currently require that samples be sent to remote labs for diagnosis. This is costly and takes time, increasing patient anxiety and delaying the start of treatment. This project will make it feasible to carry out automatic, accurate diagnosis at the local doctor's office. This will be achieved using bio-marker mRNA detection. Compared to commonly used approaches, mRNA detection avoids false positive results and has a high sensitivity. It can currently be used to detect cancer and a range of respiratory diseases, to mention a few. New bio-markers are developed every day. The partners have already developed prototype technology which partly demonstrates a microsystem operation of the mRNA approach.The project will build on this, providing the innovation needed to transform a promising technology to an integrated system suitable for practical use at point-of-care:- Provide support for all stages: cell concentration, lysis, purification, sample collection, reagent mixing, amplification and detection.-Develop disposable polymer chips for use in the portable instrument, including technology for storing all needed reagents on these chips.-Develop reliable techniques for multi-channel parallel detection (crucial for recognising disease signatures).-Address factors such as reliability, usability and cost which are crucial to acceptance by health care professionals.System accuracy will be validated on the specific case of HPV (the virus causing cervical cancer), by comparing with macroscopic results and alternative methods used at laboratories. The consortium includes two research institutes and two industrial firms (both SMEs), who have extensive experience with mRNA techniques, and are motivated to commercialise results. They will be assisted by a hospital acting as end user, validating system usability and clinical accuracy. Champ scientifique natural sciencesbiological sciencesmicrobiologyvirologynatural scienceschemical sciencespolymer sciencesmedical and health scienceshealth sciencesinfectious diseasesRNA virusescoronavirusesmedical and health sciencesclinical medicineoncologycervical cancermedical and health scienceshealth sciencesinfectious diseasesDNA viruses Mots‑clés Nanotechnology Programme(s) FP6-NMP - Nanotechnologies and nanosciences, knowledge-based multifunctional materials and new production processes and devices: thematic priority 3 under the 'Focusing and integrating community research' of the 'Integrating and strengthening the European Research Area' specific programme 2002-2006. Thème(s) NMP-2004-IST-NMP-2 - Bio-sensors for Diagnosis and Healthcare Appel à propositions Data not available Régime de financement STREP - Specific Targeted Research Project Coordinateur STIFTELSEN SINTEF Contribution de l’UE Aucune donnée Adresse Strindveien 4 7465 TRONDHEIM Norvège Voir sur la carte Coût total Aucune donnée Participants (5) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire ALBERT-LUDWIGS-UNIVERSITAET FREIBURG Allemagne Contribution de l’UE Aucune donnée Adresse FAHNENBERGPLATZ 79085 FREIBURG Voir sur la carte Coût total Aucune donnée BIOFLUIDIX GMBH Allemagne Contribution de l’UE Aucune donnée Adresse GEORGE-KOEHLER-ALLEE 106 79110 FREIBURG Voir sur la carte Coût total Aucune donnée INSTITUT FUER MIKROTECHNIK MAINZ GMBH Allemagne Contribution de l’UE Aucune donnée Adresse CARL-ZEISS-STRASSE 18-20 55129 MAINZ Voir sur la carte Coût total Aucune donnée NORCHIP AS Norvège Contribution de l’UE Aucune donnée Adresse INDUSTRIEVEIEN 8 3490 KLOKKARSTUA Voir sur la carte Coût total Aucune donnée THE COOMBE WOMEN'S HOSPITAL Irlande Contribution de l’UE Aucune donnée Adresse DOLPHINS BARN ROAD - CORK STREET DUBLIN 8 Voir sur la carte Coût total Aucune donnée
